Indigenous covacin will be approved for the second phase of testing, starting September 7

New delhi date. Sunday 6 September 2020

Indigenous covacin being developed by Bharat Biotech to prevent corona virus has been approved by the drug regulator for the second phase of the trial. According to sources, the vaccine is all set for entry into the second phase. The trial of Covexin in the second phase could begin on Monday, September 7th.

The India Biotech vaccine has been tested in the first phase in several different parts of the country. The Director General of Health Services said in a statement that there was a video conferencing between health experts on September 3 regarding the Bharat Biotech vaccine, in which it was agreed to send the vaccine to the second phase of the trial.

The second phase of the trial will now test the vaccine on 380 volunteers. All volunteers will be screened for health for the next 4 days after the vaccine is given. Preparations are underway to send India's first indigenous corona vaccine to the second phase of the trial. With the start of the second phase of the trial, the process of the first phase is also underway. More than 41 lakh people in India have been affected by corona so far.

Blood samples from previously vaccinated volunteers could be used to determine the effectiveness of the vaccine and the amount of antibody in the body. The first phase of the trial of this vaccine of Bharat Biotech did not show any side-effects.

Covexin is a joint venture between Bharat Biotech and ICMR. Hyderabad-based Bharat Biotech is one of seven Indian companies working on the Covid-19 vaccine. This is the first company. Which has received approval from the government to regulate the first and second phases to check the viability and safety of the vaccine.

Experimental vaccines are tested on people in clinical trials. To find out how safe and effective this vaccine is. This type of process usually takes 10 years. According to the WHO, people come to clinical trials voluntarily. These include drugs, surgical procedures, radiological procedures, devices, behavioral treatments, and prophylactic treatments.